Practical recommendations for the management of diabetes in patients with COVID-19.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32334646.
- Also identified by DOI 10.1016/S2213-8587(20)30152-2 and PMC identifier 7180013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2. Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress Syndrome and multi-organ failure. Depending on the global region, 20-50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had diabetes. Given the importance of the link between COVID-19 and diabetes, we have formed an international panel of experts in the field of diabetes and endocrinology to provide some guidance and practical recommendations for the management of diabetes during the pandemic. We aim to briefly provide insight into potential mechanistic links between the novel coronavirus infection and diabetes, present practical management recommendations, and elaborate on the differential needs of several patient groups.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Pandemics
- Pneumonia, Viral